pulmonary fibrosis

News

Boehringer bags FDA okay for new pulmonary fibrosis drug

Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?

News

Ten years on, Roche jettisons InterMune and Esbriet in US

It's been 10 years since Roche bought InterMune for $8.3bn on the promise of its pulmonary fibrosis drug Esbriet. Now, it's sold the business.

News

Boehringer drug scores in another pulmonary fibrosis trial

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings.

News

Pliant slumps on decision to pause lung disease drug trial

Shares in Pliant plunged after the US biotech revealed that a safety signal led it to pause a trial of its idiopathic pulmonary fibrosis drug.

News

Trial sets up filings for Boehringer IPF drug nerandomilast

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O

News

Boehringer backs Brainomix AI software for lung fibrosis

Boehringer Ingelheim has joined forces with digital health firm Brainomix on a project to improve the care of people with fibrosing lung diseases in the US.

Boehringer bags FDA okay for new pulmonary fibrosis drug

Ten years on, Roche jettisons InterMune and Esbriet in US

Boehringer drug scores in another pulmonary fibrosis trial

Pliant slumps on decision to pause lung disease drug trial

Trial sets up filings for Boehringer IPF drug nerandomilast

Boehringer backs Brainomix AI software for lung fibrosis

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

pulmonary fibrosis

Editor's Picks